Yahoo Finance

Estimated Discount To Fair Value: 11.5%

Eris Lifesciences is trading at ₹1078.9, below its fair value estimate of ₹1218.48, indicating potential undervaluation based on cash flows. Despite a recent decline in net income to ₹831.8 million for Q1 2024, revenue grew significantly to ₹7,213.6 million from the previous year’s ₹4,676.1 million. The company’s earnings are forecasted to grow at 22.3% annually over the next three years, outpacing the market's growth rate and reflecting strong future performance expectations despite current challenges.

• Our expertly prepared growth report on Eris Lifesciences implies its future financial outlook may be stronger than recent results.

• Unlock comprehensive insights into our analysis of Eris Lifesciences stock in this financial health report.

Quess

Overview: Quess Corp Limited is a business services provider operating in India, South East Asia, the Middle East, and North America with a market cap of ₹98.20 billion.

Operations: The company's revenue segments include Product Led Business (₹4.29 billion), Workforce Management (₹138.44 billion), Operating Asset Management (₹28.43 billion), and Global Technology Solutions excluding Product Led Business (₹23.87 billion).

Estimated Discount To Fair Value: 17.1%

Quess Corp, trading at ₹660.7, is undervalued relative to its fair value estimate of ₹797.12 based on discounted cash flows. Despite significant insider selling recently, Quess's earnings grew by 62.5% last year and are forecasted to grow at 23% annually over the next three years, surpassing the market's growth rate of 16.7%. Recent Q1 results show substantial revenue growth to ₹50 billion and net income doubling from a year ago, underscoring robust financial health.

• Our earnings growth report unveils the potential for significant increases in Quess' future results.

• Take a closer look at Quess' balance sheet health here in our report.

Taking Advantage

• Reveal the 28 hidden gems among our Undervalued Indian Stocks Based On Cash Flows screener with a single click here.

• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NSEI:ARVINDFASN NSEI:ERIS and NSEI:QUESS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com